Alkermes (ALKS) Tax Provisions (2010 - 2026)
Alkermes' (ALKS) quarterly Tax Provisions came in at $4.6 million in Q1 2026, up 53.33% year-on-year from $3.0 million in Q1 2025, and up 112.7% on a QoQ basis from -$36.2 million in Q4 2025.
Alkermes (ALKS) Tax Provisions (2010 - 2026) Analysis & Trends
Alkermes (ALKS) has 17 years of Tax Provisions data on file, last reported at $4.6 million in Q1 2026.
- On a quarterly basis, Tax Provisions rose 53.33% year-over-year to $4.6 million in Q1 2026; TTM through Mar 2026 was $4.1 million, a 172.24% increase from a year earlier, with the FY2025 full-year figure at $2.5 million, up 460.86% from the prior year.
- Tax Provisions for Q1 2026 stood at $4.6 million, up from -$36.2 million in the prior quarter.
- Over the last five years, Tax Provisions for ALKS reached as high as $26.8 million in Q4 2022 and fell as low as -$102.2 million in Q4 2023.
- Historically, Tax Provisions has averaged -$4.7 million across 5 years, with a median of $2.7 million in 2023.
- Across the five-year window, Tax Provisions slumped 481.88% in 2023 and jumped 1350.0% in 2024, its largest moves.
- Year by year, Tax Provisions stood at $26.8 million in 2022, then slumped by 481.88% to -$102.2 million in 2023, then jumped by 52.89% to -$48.2 million in 2024, then gained by 24.78% to -$36.2 million in 2025, then soared by 112.7% to $4.6 million in 2026.
- Per Business Quant data, the three most recent Tax Provisions figures were $4.6 million in Q1 2026, -$36.2 million in Q4 2025, and $18.0 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 88.07 Bn | 86.20 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 35.75 Bn | 32.01 Bn | 1.97 Bn | 67.00 Mn |
| 3 | Zoetis | 31.84 Bn | 29.90 Bn | 1.62 Bn | 157.00 Mn |
| 4 | Takeda Pharmaceutical | 27.18 Bn | 23.12 Bn | 4.39 Bn | 676.90 Mn |
| 5 | United Therapeutics | 23.09 Bn | 20.93 Bn | 648.10 Mn | 43.40 Mn |
| 6 | RedHill Biopharma | 21.32 Bn | 21.32 Bn | - | - |
| 7 | Viatris | 19.96 Bn | 18.16 Bn | 1.16 Bn | -423.70 Mn |
| 8 | Neurocrine Biosciences | 17.66 Bn | 16.34 Bn | 800.70 Mn | 48.90 Mn |
| 9 | Elanco Animal Health | 12.44 Bn | 12.02 Bn | 785.00 Mn | 30.00 Mn |
| 10 | Alkermes | 8.78 Bn | 8.27 Bn | 331.33 Mn | 4.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 4.60 Mn |
| Dec 31, 2025 | -36.22 Mn |
| Sep 30, 2025 | 18.00 Mn |
| Jun 30, 2025 | 17.74 Mn |
| Mar 31, 2025 | 3.00 Mn |
| Dec 31, 2024 | -48.16 Mn |
| Sep 30, 2024 | 17.40 Mn |
| Jun 30, 2024 | 22.06 Mn |
| Mar 31, 2024 | 8.00 Mn |
| Dec 31, 2023 | -102.24 Mn |
| Sep 30, 2023 | 1.20 Mn |
| Jun 30, 2023 | 2.70 Mn |
| Mar 31, 2023 | 700,000.00 |
| Dec 31, 2022 | 26.77 Mn |
| Sep 30, 2022 | -3.39 Mn |
| Jun 30, 2022 | -3.11 Mn |
| Mar 31, 2022 | -9.10 Mn |
| Dec 31, 2021 | -9.77 Mn |
| Sep 30, 2021 | 2.45 Mn |
| Jun 30, 2021 | 3.29 Mn |